



SUMMARY




Your patients with uncontrolled SHPT may be at increased risk of morbidity and mortality⁵⁻⁸




Current treatments fail to achieve balance across the key CKD-MBD parameters^{3,22-26}




KDIGO Guidelines: NVD remains unproven, while AVD and AVD analogues should be reserved for more severe SHPT in CKD stages 4 and 5²⁹




Royaldee® gradually increases 25D to the level required for sustained PTH suppression^{4,38-40}




Evidenced in two parallel, Phase 3, Randomised, placebo-controlled trials (Study A and B)²



Royaldee® significantly, reliably and sustainably reduces PTH vs placebo²



Royaldee® lowered plasma PTH consistently over time²



Royaldee® lowered plasma PTH with minimal changes in Ca, P, FGF-23^{2,39}


Royaldee® has a favourable tolerability profile, with a low risk of hypercalcaemia and hyperphosphataemia²

Mean (SE) change over 52 weeks in serum P and Ca in the per-protocol population²



Royaldee® has a favourable tolerability profile, with a low risk of hypercalcaemia and hyperphosphataemia²

Data points from 0 to 26 weeks represent mean values for individual time points from studies A and B. Error bars in this portion are omitted for clarity. Data points from 26 to 52 weeks represent mean ± SE values for data from the open-label extension study. Adapted from Sprague SM et al. 2016.²



25D = 25-hydroxyvitamin D; AVD = active vitamin D; Ca = calcium; CKD = chronic kidney disease; CKD-MBD = chronic kidney disease-mineral and bone disorder; ESRD = end stage renal disease; FGF-23 = fibroblast growth factor-23; IR = immediate release; ITT = intention-to-treat; KDIGO = Kidney Disease: Improving Global Outcomes; NVD = nutritional vitamin D; P = phosphate; PTH = parathyroid hormone; SE = standard error; SHPT = secondary hyperparathyroidism.

Click here for Prescribing Information Germany
 Click here for Prescribing Information Switzerland

HQ-RAY-2200022 | September 2022

References

1. VFMCRP Ltd. Royaldee® Summary of Product Characteristics, 2020.
2. Sprague SM et al. Am J Nephrol. 2016;44:316-325.
3. Sprague SM et al. Exp Rev Endocrinol Metab. 2017;12(5):289-301.
4. Cozzolino M et al. Expert Opin Pharmacother. 2019;20(17):2081-2093.
5. Schummock G et al. Curr Med Res Opin. 2008;24:3037-3048.
6. Cunningham J et al. Clin J Am Soc Nephrol. 2011;6:913-921.
7. Kovacs CP et al. Kidney Int. 2008;73:1286-1302.
8. Geng G et al. Osteoporos Int. 2019;30:2019-2025.
9. Moe S et al. Kidney Int. 2006;69:1945-1953.
10. Rix M et al. Kidney Int. 1999;56(3):1084-1093.
11. Qi Q et al. Am J Kidney Dis. 1995;26(4):622-631.
12. Molina P et al. Journal of Nephrology Published online: 04 January 2021 [Supplemental Material].
13. Yadhav M et al. Saudi J Kidney Dis Transpl. 2016;27:1285-1286.
14. Castro RH et al. Poster C-1002 presented at: European Congress of Radiology (ECR) 2011; 2011 March 3-7; Vienna, Austria.
15. De Boer IH et al. JASN. 2002;13(11):2762-2769.
16. Lishmanov A et al. Int Urol Nephrol. 2012;44:541-547.
17. Rodriguez M et al. Am J Renal Physiol. 2005;288:F253-264.
18. Fukuda N et al. J Clin Invest. 1993;92:1436-1443.
19. Gogusev J et al. Kidney Int. 1997;51:328-336.
20. Lau WL et al. Clin J Am Soc Nephrol. 2018;13(6):952-961.
21. Westerberg PA et al. Nephrol Dial Transplant. 2018;33(3):466-471.
22. Gunnarsson J et al. Poster presented at: 57th ERA-EDTA Congress; 2020 June 6-9; virtual.
23. Li X et al. Nephrology. 2015;20:706-714.
24. Agarwal R et al. Nephrol Dial Transplant. 2020;35(17):3176-3183.
25. Gunnarsson J et al. Nephrol Dial Transplant. 2016;31:706-713.
26. Gunnarsson J et al. Nephrol Dial Transplant. 2018;33(3):466-471.
27. Gunnarsson J et al. Nephrol Dial Transplant. 2018;33(3):466-471.
28. Li X et al. Nephrology. 2015;20:706-714.
29. Coyne DW et al. Nephrol Dial Transplant. 2013;28:2260-2268.
30. Coyne DW et al. Clin J Am Soc Nephrol. 2014;9:1620-1626.
31. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. Kidney Int Suppl. 2017;7:1-59.
32. Bover J et al. Clinical Kidney Journal. 2021;1-10.
33. Lettieri JM et al. Adv Exp Med Biol. 1977;81:591-601.
34. Bordier PJ et al. Kidney Int Suppl. 1975;2:102-112.
35. Xuli L et al. PLoS One. 2013;8:e61897.
36. Thadani R et al. JAMA. 2012;307(7):874-884.
37. Wang A et al. J Am Soc Nephrol. 2014;25:175-186.
38. Cozzolino M et al. Clin Kidney J. 2021. doi.org/10.1093/cjki/stab091.
39. Peikovitch M et al. J Steroid Biochem Mol Biol. 2015;148:283-289.
40. Strugnell SA et al. Am J Nephrol. 2019;49:284-293.
41. Sprague SM et al. Poster FP444 presented at: 58th ERA-EDTA Congress; 2019 June 13-16; Budapest, Hungary.